Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults wit…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data ...